These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 12907602

  • 1. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
    Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS.
    Cancer Res; 2003 Aug 01; 63(15):4342-6. PubMed ID: 12907602
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS.
    Cancer Res; 2002 May 15; 62(10):2731-5. PubMed ID: 12019144
    [Abstract] [Full Text] [Related]

  • 3. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.
    Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F.
    Cancer Res; 2001 Jun 01; 61(11):4341-4. PubMed ID: 11389057
    [Abstract] [Full Text] [Related]

  • 4. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
    Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS.
    Cancer Res; 2005 Aug 15; 65(16):7045-51. PubMed ID: 16103050
    [Abstract] [Full Text] [Related]

  • 5. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
    Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS.
    Cancer Res; 2004 Jun 01; 64(11):3994-4000. PubMed ID: 15173013
    [Abstract] [Full Text] [Related]

  • 6. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.
    Anticancer Res; 2004 Jun 01; 24(3a):1759-63. PubMed ID: 15274352
    [Abstract] [Full Text] [Related]

  • 7. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
    Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V.
    Cancer Res; 2003 Dec 01; 63(23):8408-13. PubMed ID: 14679003
    [Abstract] [Full Text] [Related]

  • 8. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors.
    Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L, Bertolini F.
    Clin Cancer Res; 2003 Jan 01; 9(1):377-82. PubMed ID: 12538491
    [Abstract] [Full Text] [Related]

  • 9. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS.
    Cancer Res; 2006 Apr 01; 66(7):3386-91. PubMed ID: 16585158
    [Abstract] [Full Text] [Related]

  • 10. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E, Barichello JM, Ishida T, Kiwada H.
    Int J Pharm; 2008 Apr 02; 353(1-2):65-73. PubMed ID: 18155369
    [Abstract] [Full Text] [Related]

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 12. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS.
    Breast; 2005 Dec 15; 14(6):466-79. PubMed ID: 16199161
    [Abstract] [Full Text] [Related]

  • 13. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 14. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M.
    Clin Cancer Res; 2006 Sep 01; 12(17):5190-8. PubMed ID: 16951238
    [Abstract] [Full Text] [Related]

  • 15. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.
    Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP, Folkman J, Soker S.
    Cancer Res; 2003 Dec 01; 63(23):8345-50. PubMed ID: 14678995
    [Abstract] [Full Text] [Related]

  • 16. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS.
    Mol Cancer Ther; 2009 Oct 01; 8(10):2872-81. PubMed ID: 19825805
    [Abstract] [Full Text] [Related]

  • 17. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Oct 01; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 18. [Changes and significance of peripheral blood platelet count in tumor shrinkage induced by a low dose of CTX in T739 mice].
    Li ML, Jia YJ, Jiang MN, Shu XH, Li CG.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jun 01; 24(6):567-9. PubMed ID: 18538085
    [Abstract] [Full Text] [Related]

  • 19. Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients.
    Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T, Peters SO.
    In Vivo; 2008 Jun 01; 22(6):831-6. PubMed ID: 19181016
    [Abstract] [Full Text] [Related]

  • 20. Estradiol-induced, endothelial progenitor cell-mediated neovascularization in male mice with hind-limb ischemia.
    Ruifrok WP, de Boer RA, Iwakura A, Silver M, Kusano K, Tio RA, Losordo DW.
    Vasc Med; 2009 Feb 01; 14(1):29-36. PubMed ID: 19144777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.